Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bangladesh Beximco Starts Drugs Exports to Jordan (Bangladesh)

This article was originally published in PharmAsia News

Executive Summary

Bangladesh's top drug maker, Beximco Pharmaceuticals announced Sept. 30 that it will soon begin exporting medicines to Jordan. So far, Beximco has received approval for four different treatments, with several other applications in the works. Jordan has a pharmaceutical market worth an estimated $315 million that primarily relies on imports. The country also boasts a strong infrastructure, a well-regulated healthcare system, and strong trading partnerships throughout the Middle East. Representatives for Beximco say these factors make the country an ideal entry point for the company into the region's markets. (Click here for more

You may also be interested in...



US FDA Waives Warning Cap Requirement For Neuromuscular Agents As Demand Outranks Safety Worries

COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.

Next Generation SERDs Progress In Breast Cancer; Standing Out In The Crowd Won't Be Easy

The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.

Medtronic And Titan Medical Sign Licensing, Development Agreements For Robotic Surgeries

Medtronic has agreed to licensing and development agreements with cash-strapped surgical robotics company Titan receiving payments up to $31m pending certain milestones.

UsernamePublicRestriction

Register

LL044113

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel